Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Atara Biotherapeutics Inc    ATRA

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
28.25(c) 27.55(c) 28.25(c) 27.5(c) 29.5(c) Last
3 694 766 2 440 554 1 709 929 655 029 1 238 947 Volume
+27.54% -2.48% +2.54% -2.65% +7.27% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -122 M
Net income 2017 -119 M
Finance 2017 60,2 M
Yield 2017 -
Sales 2018 1,30 M
EBIT 2018 -156 M
Net income 2018 -151 M
Finance 2018 35,1 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 620x
Capitalization 841 M
More Financials
Company
Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology.Its product candidates are biologics targeting myostatin and activin, members of the... 
More about the company
Surperformance© ratings of Atara Biotherapeutics Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on ATARA BIOTHERAPEUTICS INC
01/10 ATARA BIOTHERAPEUTICS : Announces FDA Clearance to Proceed with Enrollment at U...
01/05 ATARA BIOTHERAPEUTICS : Starts Two Phase 3 Trials of Treatment for Lymphoma That..
01/05 ATARA BIOTHERAPEUTICS : BioCentury - Atara prices $127.8M follow-on
01/05 ATARA BIOTHERAPEUTICS, INC. (NASDAQ : ATRA) Files An 8-K Other Events
01/04 ATARA BIOTHERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (f..
01/04 Atara Biotherapeutics to Present at the 36th Annual J.P. Morgan Healthcare Co..
01/04 ATARA BIOTHERAPEUTICS : Announces Pricing of Public Offering of Common Stock
01/04 Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
01/03 ATARA BIOTHERAPEUTICS : Announces Proposed Offering of Common Stock
01/03 ATARA BIOTHERAPEUTICS : Announces Initiation of Two Phase 3 Clinical Studies to ..
More news
Sector news : Bio Therapeutic Drugs
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Bio Therapeutic Drugs
Latest Tweets
01/19Man of steel John McGrath bending the world to his will  
01/19Atara Biotherapeutics stock price target raised to $70 from $47 at Canaccord .. 
01/19Trndg ? $ESV $CPG $SN $ATRA $GE $WTI $VRX Charts @  
01/19$ATRA PT raised to $70 from $47 at Canaccord
4
01/19Allsup Names John McGrath New Director of Business Development  
More tweets
Qtime:71
News from SeekingAlpha
01/19 JUNO THERAPEUTICS : What The Celgene Potential Acquisition Foretells
01/19 PREMARKET GAINERS AS OF 9 : 05 am (1/19/2018)
01/19 Premarket analyst action - healthcare
01/14 APLS - Addendum, How A Company Tries To Make Lemonade Out Of Lemons
01/12 Atara Bio builds on ATA188-stoked up move, shares ahead 35%
Chart ATARA BIOTHERAPEUTICS INC
Duration : Period :
Atara Biotherapeutics Inc Technical Analysis Chart | ATRA | US0465131078 | 4-Traders
Technical analysis trends ATARA BIOTHERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 29,6 $
Spread / Average Target 7,6%
EPS Revisions
Managers
NameTitle
Issac E. Ciechanover Chairman, President & Chief Executive Officer
John F. McGrath Chief Financial Officer & Executive Vice President
Christopher M. Haqq Chief Scientific Officer, Executive VP-R&D
Joe Newell Chief Technical Operations Officer & Executive VP
Kanya Rajangam Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ATARA BIOTHERAPEUTICS INC51.93%841
GILEAD SCIENCES14.10%106 002
REGENERON PHARMACEUTICALS-0.50%39 890
VERTEX PHARMACEUTICALS4.76%39 754
GENMAB10.50%11 455
BLUEBIRD BIO INC2.25%8 346